The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sangamo Therapeutics Inc

Nasdaq: SGMO
Last

(U.S.) $9.43

Today's change-0.13 -1.31%
Updated July 21 3:50 PM EDT. Delayed by at least 15 minutes.
 

Sangamo Therapeutics Inc

Nasdaq: SGMO
Last

(U.S.) $9.43

Today's change-0.13 -1.31%
Updated July 21 3:50 PM EDT. Delayed by at least 15 minutes.

Sangamo Therapeutics Inc down (U.S.)$0.13

Sangamo Therapeutics Inc closed lower Friday, dropping (U.S.)$0.13 or 1.31% to (U.S.)$9.43. Shares have lost 6.68% over the last five days, but have gained 209.02% over the last year to date. This security has outperformed the S&P 500 by 46.96% during the last year.

Key company metrics

  • Open(U.S.) $9.60
  • Previous close(U.S.) $9.55
  • High(U.S.) $9.70
  • Low(U.S.) $9.30
  • Bid / Ask(U.S.) $9.40 / (U.S.) $9.45
  • YTD % change+209.02%
  • Volume1,045,534
  • Average volume (10-day)1,267,663
  • Average volume (1-month)1,425,422
  • Average volume (3-month)1,311,713
  • 52-week range(U.S.) $2.65 to (U.S.) $10.50
  • Beta3.27
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.02
Updated July 21 3:50 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue3934
Total other revenue--------
Total revenue3934
Gross profit--------
Total cost of revenue--------
Total operating expense20192231
Selling / general / administrative75511
Research & development13141719
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-17-10-19-27
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-17-10-19-27
Income after tax-17-10-19-27
Income tax, total--000
Net income-17-10-19-27
Total adjustments to net income--------
Net income before extra. items-17-10-19-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17-10-19-27
Inc. avail. to common incl. extra. items-17-10-19-27
Diluted net income-17-10-19-27
Dilution adjustment--------
Diluted weighted average shares71717170
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.14-0.27-0.38
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.23-0.14-0.27-0.38